The company was founded.
Obtained the patent of "A method and a culture system for efficiently expanding activated lymphocytes".
Conduct EAL® (Expanded Activated lymphocytes) pre-clinical studies.
Research on CAR-T cell technology has begun.
Submit an IND application for EAL® products.
EAL® Phase II clinical trial approval was obtained.
Start CAR-T-19 pre-clinical research on research products.
Conducting Phase II clinical trials of EAL® products.
Submit an IND application for CAR T-19 injection.
It has been ethically approved by the China Registered Clinical Trials Ethics Review Committee to conduct clinical studies of CAR-T-19-DNR in research products.
Successfully listed on the Hong Kong Stock Exchange under the stock code 06978.HK.
CAR-T-19 Injection obtained clinical trial approval.
The company's cellular immunotherapy drug industrialization project (120,000 square meters) has been officially started construction.
China Resources Pharmaceutical strategic investment company, accounting for 10% of the stock.
The company obtained the exclusive license in the NIH for R&D registration and commercialization of TCR therapy targeting HERV-E in renal cell carcinoma in China and South Korea.
The company's new tumour product-immune cell product industrialization project (17,000 square meters) was completed.
Obtained Phase I clinical trial approval for Denocabtagene Ciloleucel Injection (originally known as RC19D2, CAR-T-D2, CAR-T-19-DNR)